Is tesamorelin a weight-loss drug?

The short answer

“Reduces abdominal fat” and “is a weight-loss drug” are not interchangeable claims. Tesamorelin’s labeled indication is narrow: excess abdominal fat in adults with HIV-associated lipodystrophy. The label explicitly excludes weight-loss management, and its limitation statement says long-term cardiovascular safety has not been established. [1]

Visceral fat was the endpoint—not scale weight

The Phase 3 program used 26-week, randomized, double-blind, placebo-controlled studies, with visceral adipose tissue measured by CT as the primary outcome. The completed trial record for NCT00123253—also identified by the alias NCT00435136—likewise lists visceral adipose tissue as its primary outcome. [1] [3]

That distinction matters. A CT scan can quantify a specific internal fat compartment; a scale reports total body weight. Evidence for change in one endpoint should not be relabeled as evidence for another. The label’s own weight-neutral limitation reinforces that boundary. [1]

What the pivotal randomized trial actually showed

In the 26-week trial reported by Falutz and colleagues, participants were randomized to tesamorelin or placebo and the primary endpoint was CT-measured visceral adipose tissue. More participants receiving tesamorelin withdrew because of an adverse event. The abstract reported no significant between-group difference in glycemic measures during this trial. [2]

The defensible reading is specific: the trial showed a visceral-fat result in adults with HIV and abdominal fat accumulation. It did not establish tesamorelin as a general weight-loss treatment. [2] [1]

Mechanism is not proof of every marketed use

Tesamorelin is a growth hormone–releasing factor/hormone analog. It stimulates endogenous growth hormone and increases IGF-1. That mechanism helps explain why the label calls for attention to IGF-1, but a biological mechanism does not extend an approval beyond the population and outcome actually studied. [1]

Safety and evidence boundaries

The current label’s warnings and precautions address malignancy, elevated IGF-1, fluid retention, glucose intolerance or diabetes, and hypersensitivity. Its contraindications include active malignancy, pregnancy, disruption of the hypothalamic-pituitary axis, and hypersensitivity. These are reasons to treat the current label and prescriber-led monitoring as central—not as fine print. [1]

This page is educational and does not provide dosing, timing, or treatment instructions. Questions about whether tesamorelin fits a person’s situation, and every schedule decision, belong with the prescriber and current product labeling.

What the label says about stopping, IGF-1, blood sugar and antibodies

The benefit lasts only while the drug is taken. In the trials’ extension phases, visceral fat rose 22% and 16% over 26 weeks in patients switched from tesamorelin to placebo, and the second trial’s authors wrote that the gains were “rapidly lost.” [1] [4]

Tesamorelin raises IGF-1, and often above the normal range: at 26 weeks, 47% of patients had IGF-1 more than 2 standard deviations above normal and 36% more than 3. The label says “the effects of prolonged elevations in IGF-1 levels are unknown” and calls for monitoring. New diabetes-range blood sugar (HbA1c of 6.5% or more) occurred in 5% of patients versus 1% on placebo. [1]

Half of patients developed antibodies to tesamorelin by 26 weeks. In about 60% of those, the antibodies also reacted with the body’s own growth hormone–releasing hormone, and at week 52, 10% had antibodies that neutralized tesamorelin and 5% had antibodies that neutralized natural GHRH in lab tests. [1] That matters for unapproved GHRH analogs such as CJC-1295, which have no comparable data; see our CJC-1295 and ipamorelin teardown.

Can you get tesamorelin from a compounding pharmacy or a “research” seller?

Not through the routes FDA recognizes, by FDA’s own documents. FDA approved tesamorelin as Egrifta on November 10, 2010 (application 022505). On March 23, 2020, it was one of the approved products that federal law moved to biologic status: FDA’s list of applications “deemed to be BLAs” (biologics licenses) that day includes tesamorelin acetate, Egrifta. [5]

That change matters for compounding. FDA’s guidance on biological products says the compounding exemptions in sections 503A and 503B of the drug law cover the drug-approval requirement, but “they do not provide an exemption from the requirement to obtain premarket approval under section 351 of the PHS Act,” which is the biologics license. [6] Our reading of those two documents together, which is analysis and not legal advice, is that the usual compounding-pharmacy route does not cover tesamorelin.

Online sellers that label tesamorelin “for research use only” are a separate case. In at least five warning letters dated August 24, 2026, FDA said products sold online as tesamorelin, including one sold as a tesamorelin and ipamorelin blend, are unapproved new drugs. FDA wrote that despite the “research use only” or “not for human” labels, evidence from the sellers’ websites, including selling bacteriostatic water for mixing the products, showed they were intended for human use. [7] [8] [9] [10] [11] Those are FDA’s findings in letters; a warning letter is not a court ruling. Egrifta’s approval covers Egrifta, not these products.

Tesamorelin is not approved in the European Union. The company withdrew its application on June 21, 2012, and the European Medicines Agency says that at the time its committee “was of the provisional opinion that Egrifta could not have been approved.” [12]

What is still being studied: a randomized trial called TRIUMPH (not related to Lilly’s retatrutide trials of the same name) is testing tesamorelin or placebo, both added to home exercise, in 100 older adults with HIV, looking at physical function. ClinicalTrials.gov lists it as recruiting, with main results expected around June 2028, so there are no results yet. [13] [14]

Frequently asked questions

Sources opened and checked

1. [1] Current EGRIFTA WR labeling, DailyMed set ID 839334d3-8c1d-4c26-9036-2ab524a6ea75 — current version published August 3, 2026 (first published July 15, 2025). Checked October 16, 2026.
2. [2] Falutz et al., New England Journal of Medicine (2007), PMID 18057338, “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” Checked October 16, 2026.
3. [3] ClinicalTrials.gov, NCT00123253 (NCT00435136 listed as an alias), “TH9507 in Patients With HIV-Associated Lipodystrophy,” completed. Checked October 16, 2026.
4. [4] Falutz et al., Journal of Acquired Immune Deficiency Syndromes (2010), PMID 20101189, “Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension” (404 patients; visceral fat −10.9% vs −0.6% at 6 months). Checked October 17, 2026.
5. [5] FDA, “List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020” (lists tesamorelin acetate, Egrifta, application 022505, approved 11/10/2010). Checked October 24, 2026.
6. [6] FDA guidance for industry, “Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application” (January 2018), section II.C. Checked October 24, 2026.
7. [7] FDA warning letter, MARCS-CMS 733652, August 24, 2026. Checked October 24, 2026.
8. [8] FDA warning letter, MARCS-CMS 735063, August 24, 2026. Checked October 24, 2026.
9. [9] FDA warning letter, MARCS-CMS 734884, August 24, 2026. Checked October 24, 2026.
10. [10] FDA warning letter, MARCS-CMS 735067, August 24, 2026. Checked October 24, 2026.
11. [11] FDA warning letter, MARCS-CMS 735127, August 24, 2026. Checked October 24, 2026.
12. [12] European Medicines Agency, “Egrifta: Withdrawn application” (withdrawal notified June 21, 2012). Checked October 24, 2026.
13. [13] ClinicalTrials.gov, NCT06554717, “Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV,” recruiting; estimated primary completion June 16, 2028. Checked October 24, 2026.
14. [14] Erlandson KM, Fourman LT et al., BMJ Open (2026) 16(7):e120740, TRIUMPH trial protocol. Checked October 24, 2026.

Related reading